Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BioNexus Gene Lab Corp

Get SEC filing alerts via email and in your feed for BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

About BioNexus Gene Lab Corp

BioNexus Gene Lab Corp. operates through two subsidiaries: Chemrex, which distributes fiber-reinforced polymer (FRP) chemical raw materials to manufacturers in Southeast Asia, and MRNA Scientific, which develops non-invasive RNA-based liquid biopsy tests for early detection of cancers and inflammatory diseases. The company serves industrial manufacturers and healthcare providers, leveraging proprietary genomic screening technology and extensive regional distribution to offer specialized diagnostics and chemical materials with technical expertise and broad product ranges.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BioNexus Gene Lab Corp

1
1
BioNexus Gene Lab Corp BioNexus Gene Lab Corp. Reports 99% Revenue Decline in Q1 2026

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
BioNexus Gene Lab Corp BioNexus Gene Lab Corp. Reports 21.9% Revenue Decline and Increased Losses for Fiscal Year 2025

Via official filing (AI summary) | about 2 months ago | 0 comments

3
1
BioNexus Gene Lab Corp BioNexus Gene Lab Corp. Reports Q3 Revenue of $2.54M, Net Loss Improves

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BioNexus Gene Lab Corp BioNexus Gene Lab Reports 14.5% Revenue Growth in Q2 2025 Despite Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BioNexus Gene Lab Corp BioNexus Gene Lab Corp. Reports 10.3% Revenue Decline in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BioNexus Gene Lab Corp BioNexus Gene Lab Corp. Reports 6.8% Revenue Decline, Net Loss Improvement in Nine Months Ending September 30, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments